South and Central America Late Stage Chronic Kidney Disease Drugs Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product Type (Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Others); Indication (Late Stage Chronic Kidney Disease Induced Hyperparathyroidism, Late Stage Chronic Kidney Disease Induced Hyperphosphatemia, Late Stage Chronic Kidney Disease Induced Hyperkalaemia); Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies); and Country

Code: TIPRE00018210 | Pages: 92 | Industry: Pharmaceuticals | Date: Jan 2021
Covid

Market Introduction

Late-stage renal disease, also defined as end-stage kidney disease, occurs with the gradual loss of kidney function at an advanced state. In end-stage renal disease, kidneys can no longer filter wastes, and excess fluids from blood and wastes can build up in the body.

 


Get more information on this report :



Market Overview and Dynamics

The South and Central America late-stage chronic kidney disease drugs market is expected to reach US$ 842.25 million by 2027 from US$ 379.82 million in 2019; the market is estimated to grow at a CAGR of 10.7% from 2020 to 2027. The high prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policies for the late-stage chronic kidney disease treatments are among the key factors driving the market growth in this region. However, delay in the diagnosis of chronic kidney diseases hampers the market growth.

 

Key Market Segments

On the basis of product type, the South and Central America late-stage chronic kidney disease drugs market is segmented into calcimimetics, vitamin D, potassium binders, calcium-based phosphate binders, and others. The calcimimetics segment held the largest share of the market in 2019, and it is expected to register the highest CAGR during the forecast period.

The South and Central America late-stage chronic kidney disease drugs market, by indication, is segmented into late-stage chronic kidney disease induced hyperparathyroidism, late-stage chronic kidney disease induced hyperphosphatemia, and late-stage chronic kidney disease induced hyperkalemia. The late-stage chronic kidney disease induced hyperparathyroidism segment held the largest market share in 2019, and it is anticipated to register the highest CAGR in the market during the forecast period.

Based on distribution channel, the South and Central America late-stage chronic kidney disease drugs market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacies segment held the largest share of the market in 2019; however, the market for online pharmacies is estimated to grow at the highest CAGR during 2020–2027.

 

Major Sources and Companies Listed

Some of the primary and secondary sources associated with this report on the South and Central Americalate stage chronic kidney disease drugs market are National Center for Biotechnology Information (NCBI); Centers for Disease Control and Prevention (CDC); and National Institutes of Health (NIH).

 

Reasons to buy the report

·         Determine prospective investment areas based on a detailed trend analysis of the South and Central Americalate stage chronic kidney disease drugs market over the next years.

·         Gain an in-depth understanding of the underlying factors driving demand for different addictions therapeutics segments in the top spending countries and identify the opportunities offered by each of them.

·         Strengthen your knowledge of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.

·         Identify the major channels driving theSouth and Central Americalate stage chronic kidney disease drugs market, providing a clear picture of future opportunities that will help Analyze, resulting in revenue expansion.

·         Channelize resources by focusing on the ongoing programs undertaken by the different countries within the South and Central Americalate stage chronic kidney disease drugs market.

 

 

 

SOUTH AND CENTRAL AMERICALATE STAGE CHRONIC KIDNEY DISEASE DRUGS MARKET SEGMENTATION

By Product Type

·      Calcimimetics

·      Vitamin D

·      Sterols

·      Potassium Binders

·      Calcium-Based Phosphate Binders

 

By Indication

·      Late Stage Chronic Kidney Disease Induced Hyperparathyroidism

·      Late Stage Chronic Kidney Disease Induced Hyperphosphatemia

·      Late Stage Chronic Kidney Disease Induced Hyperkalaemia

·      Others

 

By Distribution Channel

·      Hospital Pharmacies

·      Online Pharmacies

·      Retail Pharmacies

 

By Country

·      Brazil

·      Argentina

·      Rest of South and Central America

 

Company Profiles

·         AbbVie Inc

·         Amgen

·         AstraZeneca

·         Sanofi

·         Kyowa Kirin Co., Ltd

·         Bayer AG

·         Vifor Pharma Management Ltd

·         Akebia Therapeutics, Inc

 

 

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 South and Central America Late Stage Chronic Kidney Disease Drugs Market – By Product Type

1.3.2 South and Central America Late Stage Chronic Kidney Disease Drugs Market – By Indication

1.3.3 South and Central America Late Stage Chronic Kidney Disease Drugs Market – By Distribution Channel

1.3.4 South and Central America Late Stage Chronic Kidney Disease Drugs Market – By Country

2. Late Stage Chronic Kidney Disease Drugs Market – Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Late Stage Chronic Kidney Disease Drugs Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 South & Central America (SCAM) – PEST Analysis

4.3 Expert Opinion

5. Late Stage Chronic Kidney Disease Drugs Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 High Prevalence of Diseases Leading to Chronic Kidney Diseases

5.1.2 Favourable Reimbursement Policy for the Late Stage Chronic Kidney Disease Drugs

5.2 Market Restraints

5.2.1 Delay in the Diagnosis of Chronic Kidney Disease

5.3 Market Opportunities

5.3.1 Introduction of New Late Stage Chronic Kidney Disease Drugs

5.4 Future Trends

5.4.1 Introduction of New Preclinical Models to Improve Target Validation and Understand Disease Development

5.5 Impact Analysis

6. Late Stage Chronic Kidney Disease Drugs Market – South and Central America Analysis

6.1 South and Central America Late Stage Chronic Kidney Disease Drugs Market Revenue Forecast and Analysis

7. Late Stage Chronic Kidney Disease Drugs Market Analysis – By Product Type

7.1 Overview

7.2 Late Stage Chronic Kidney Disease Drugs Market Revenue Share, by Late Stage Chronic Kidney Disease Drugs by Product Type (2019 and 2027)

7.3 Calcimimetics

7.3.1 Overview

7.3.2 Calcimimetics: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

7.4 Vitamin D

7.4.1 Overview

7.4.2 Vitamin D: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

7.5 Potassium Binders

7.5.1 Overview

7.5.2 Potassium Binders: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

7.6 Calcium-Based Phosphate Binders

7.6.1 Calcium-Based Phosphate Binders: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

7.7 Others

7.7.1 Others: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

8. Late Stage Chronic Kidney Disease Drugs Market Analysis by Indication

8.1 Overview

8.2 Late Stage Chronic Kidney Disease Drugs Market Revenue Share, by Indication (2019 and 2027)

8.3 Late Stage Chronic Kidney Disease Induced Hyperparathyroidism

8.3.1 Overview

8.3.2 Late Stage Chronic Kidney Disease Induced Hyperparathyroidism: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

8.4 Late Stage Chronic Kidney Disease Induced Hyperphosphatemia

8.4.1 Overview

8.4.2 Late Stage Chronic Kidney Disease Induced Hyperphosphatemia: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

8.5 Late Stage Chronic Kidney Disease Induced Hyperkalemia

8.5.1 Overview

8.5.2 Late Stage Chronic Kidney Disease Induced Hyperkalemia: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

9. Late Stage Chronic Kidney Disease Drugs Market Analysis by Distribution Channel

9.1 Overview

9.2 Late Stage Chronic Kidney Disease Drugs Market Share, by Distribution Channel, 2019 and 2027, (%)

9.3 Hospital Pharmacies

9.3.1 Overview

9.3.2 Hospital Pharmacies: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

9.4 Online Pharmacies

9.4.1 Overview

9.4.2 Online Pharmacies: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

9.5 Retail Pharmacies

9.5.1 Overview

9.5.2 Retail Pharmacies Segment: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

10. Late Stage Chronic Kidney Disease Drugs Market Analysis and Forecasts To 2027 – Geographical Analysis

10.1 South and Central America: Late Stage Chronic Kidney Disease Drugs Market

10.1.1 Overview

10.1.2 South and Central America: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

10.1.3 South and Central America Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

10.1.4 South and Central America Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

10.1.5 South and Central America Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027(USD Million)

10.1.6 South and Central America: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019& 2027 (%)

10.1.7 Brazil: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

10.1.7.1 Brazil: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

10.1.7.2 Brazil Late Stage Chronic Kidney Disease Drugs Market, by Product Type– Revenue and Forecast to 2027 (USD Million)

10.1.7.3 Brazil Late Stage Chronic Kidney Disease Drugs Market, by Indication– Revenue and Forecast to 2027 (USD Million)

10.1.7.4 Brazil Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027(USD Million)

10.1.8 Argentina: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

10.1.8.1 Argentina: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

10.1.8.2 Argentina Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

10.1.8.3 Argentina Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

10.1.8.4 Argentina Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027(USD Million)

11. Impact of COVID-19 Pandemic on South and Central America Late Stage Chronic Kidney Disease Drugs Market

11.1 South and Central America: Impact Assessment of COVID-19 Pandemic

12. Company Profiles

12.1 AbbVie Inc.

12.1.1 Key Facts

12.1.2 Business Description

12.1.3 Products and Services

12.1.4 Financial Overview

12.1.5 SWOT Analysis

12.1.6 Key Developments

12.2 Amgen

12.2.1 Key Facts

12.2.2 Business Description

12.2.3 Products and Services

12.2.4 Financial Overview

12.2.5 SWOT Analysis

12.2.6 Key Developments

12.3 AstraZeneca

12.3.1 Key Facts

12.3.2 Business Description

12.3.3 Products and Services

12.3.4 Financial Overview

12.3.5 SWOT Analysis

12.3.6 Key Developments

12.4 Sanofi

12.4.1 Key Facts

12.4.2 Business Description

12.4.3 Products and Services

12.4.4 Financial Overview

12.4.5 SWOT Analysis

12.4.6 Key Developments

12.5 Kyowa Kirin Co., Ltd

12.5.1 Key Facts

12.5.2 Business Description

12.5.3 Products and Services

12.5.4 Financial Overview

12.5.5 SWOT Analysis

12.5.6 Key Developments

12.6 Bayer AG

12.6.1 Key Facts

12.6.2 Business Description

12.6.3 Products and Services

12.6.4 Financial Overview

12.6.5 SWOT Analysis

12.6.6 Key Developments

12.7 Vifor Pharma Management Ltd.

12.7.1 Key Facts

12.7.2 Business Description

12.7.3 Products and Services

12.7.4 Financial Overview

12.7.5 SWOT Analysis

12.7.6 Key Developments

12.8 Akebia Therapeutics, Inc.

12.8.1 Key Facts

12.8.2 Business Description

12.8.3 Products and Services

12.8.4 Financial Overview

12.8.5 SWOT Analysis

12.8.6Key Developments

13. Appendix

13.1 Glossary of Terms


LIST OF TABLES

Table 1. South and Central America Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

Table 2. South and Central America Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

Table 3. South and Central America Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel– Revenue and Forecast to 2027(USD Million)

Table 4. Brazil Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

Table 5. Brazil Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

Table 6. Brazil Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027(USD Million)

Table 7. Argentina Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)

Table 8. Argentina Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)

Table 9. Argentina Late Stage Chronic Kidney Disease Drugs Market, by Distribution Channel – Revenue and Forecast to 2027(USD Million)

Table 10. Glossary of Terms, Late Stage Chronic Kidney Disease Drugs Market


LIST OF FIGURES

Figure 1. Late Stage Chronic Kidney Disease Drugs Market Segmentation

Figure 2. Late Stage Chronic Kidney Disease Drugs Market – By country

Figure 3. South and Central America Late Stage Chronic Kidney Disease Drugs Market Overview

Figure 4. Calcimimetics Segment Held Largest Share of Late Stage Chronic Kidney Disease Drugs Market

Figure 5. South and Central America Late Stage Chronic Kidney Disease Drugs Market- Leading Country Markets (US$ Million)

Figure 6. South & Central America (SCAM) PEST Analysis

Figure 7. Late Stage Chronic Kidney Disease Drugs Market Impact Analysis of Driver and Restraints

Figure 8. South and Central America Late Stage Chronic Kidney Disease Drugs Market – Revenue Forecast and Analysis – 2019- 2027

Figure 9. Late Stage Chronic Kidney Disease Drugs Market Revenue Share, by Late Stage Chronic Kidney Disease Drugs by Product Type (2019 and 2027)

Figure 10. Calcimimetics: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

Figure 11. Vitamin D: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

Figure 12. Potassium Binders: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

Figure 13. Calcium-Based Phosphate Binders: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

Figure 14. Others: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

Figure 15. Late Stage Chronic Kidney Disease Drugs Market Revenue Share, by Indication (2019 and 2027)

Figure 16. Late Stage Chronic Kidney Disease Induced Hyperparathyroidism: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

Figure 17. Late Stage Chronic Kidney Disease Induced Hyperphosphatemia: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

Figure 18. Late Stage Chronic Kidney Disease Induced Hyperkalemia: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

Figure 19. Late Stage Chronic Kidney Disease Drugs Market Share, by Distribution Channel, 2019 and 2027 (%)

Figure 20. Hospital Pharmacies: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

Figure 21. Online Pharmacies: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

Figure 22. Retail Pharmacies: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)

Figure 23. South and Central America: Late Stage Chronic Kidney Disease Drugs Market, by Key Country – Revenue (2019) (USD Million)

Figure 24. South and Central America Late Stage Chronic Kidney Disease Drugs Market Revenue and Forecast to 2027 (USD Million)

Figure 25. South and Central America: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)

Figure 26. Brazil: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

Figure 27. Argentina: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)

Figure 28. Impact of COVID-19 Pandemic on Late Stage Chronic Kidney Disease Drugs Market in South and Central America

 

 

  1.          AbbVie Inc
  2.          Amgen
  3.          AstraZeneca
  4.          Sanofi
  5.          Kyowa Kirin Co., Ltd
  6.          Bayer AG
  7.          Vifor Pharma Management Ltd
  8.          Akebia Therapeutics, Inc
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the South and Central America Last Stage Chronic Kidney Disease Drugs market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the  South and Central AmericaLast Stage Chronic Kidney Disease Drugs market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

 

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Related Tags South and Central America Late Stage Chronic Kidney Disease Drugs Market South and Central America Late Stage Chronic Kidney Disease Drugs Market Research South and Central America Late Stage Chronic Kidney Disease Drugs Market Insight South and Central America Late Stage Chronic Kidney Disease Drugs Market Trends South and Central America Late Stage Chronic Kidney Disease Drugs Market Forecast South and Central America Late Stage Chronic Kidney Disease Drugs Market Share South and Central America Late Stage Chronic Kidney Disease Drugs Market 2027 South and Central America Late Stage Chronic Kidney Disease Drugs Market Growth South and Central America Late Stage Chronic Kidney Disease Drugs Industry Sector South and Central America Late Stage Chronic Kidney Disease Drugs PDF Report South and Central America Late Stage Chronic Kidney Disease Drugs Analysis South and Central America Late Stage Chronic Kidney Disease Drugs Research Competitive Analysis

Purchase Options
Single User License
$3000
Site License
$4000
Enterprise License
$5000